AAIC Stock Recent News

NEWTON, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), will present new findings at the upcoming Alzheimer's Association International Conference (AAIC®) 2025 in Toronto. The presentations include a cost savings analysis of the use of pTau217 as a screening tool in Acumen's Phase 2 ALTITUDE-AD trial of sabirnetug as well as a nonclinical study evaluating the relative selectivity of sabirnetug to targeting AβOs versus Aβ monomers. The conference will be held July 27-31, 2025, both in-person and online.

MALVERN, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced its senior management will attend the Alzheimer's Association International Conference (AAIC), taking place July 27–31, 2025, in Toronto, Canada.

We take a look at the action in preferreds and baby bonds through the third week of December and highlight some of the key themes we are watching. Preferreds rallied as Treasury yields fell, bringing year-to-date total return to around 9%. AAIC announced plans to delist and deregister its two baby bonds, citing compliance costs outweighing benefits.

U.S. equity markets extended their rebound to a third-straight week as benchmark interest rates dipped on economic data and corporate earnings reports showing a more distinct cooldown in economic activity. Gaining for a third-straight week and extending its rebound to nearly 10% since dipping into "correction territory" at the end of October, the S&P 500 gained another 2.4% this week. Lifted by the retreat in benchmark interest rates, real estate equities have roared back to life over the past three weeks. Equity REITs and Mortgage REITs each gained another 4.7%.

Arlington Asset Investment Corp. invests in mortgage-backed assets and has not paid dividends since the start of the COVID pandemic. Arlington has been able to generate consistent operating income and has a debt-to-equity ratio of 2.67. Ellington Financial LLC has entered into a merger agreement to acquire Arlington, offering a premium to Arlington shareholders and expecting to benefit from Arlington's assets.

Bond prices tumble as PPI exceeds expectations, raising the 10y US T-Note yield to 4.15%. Arlington Asset Investment Corp.'s Series C Fixed-to-Floating Rate Cumulative Redeemable Preferred presents an opportunity in the changing environment. AAIC.PC has a low number of shares outstanding and a potential 13% net return over the next eight months.

We take a look at the action in preferreds and baby bonds through the second week of July and highlight some of the key themes we are watching. Preferreds rallied this week, buoyed by a disinflationary theme that has supported markets recently. We take a look at a couple of metrics outside of leverage to gauge debt quality.

We take a look at the action in preferreds and baby bonds through the third week of June and highlight some of the key themes we are watching. Preferreds were roughly flat as higher Treasury yields were offset by tighter credit spreads. We take a look at a couple of pricing discrepancies in the B. Riley Financial senior security suite, which are indicative of broader market inefficiencies.

Ellington Financial (EFC) enters into an agreement to acquire Arlington (AAIC) in a stock-and-cash transaction. This deal is likely to increase scale and provide greater access to capital markets.

Big yields and even bigger discounts on each share here. A buyout drove one of our positions up about 40% in a day. The REITs we're highlighting here don't unusually trade at such large discounts to book value.